JP2003503042A - ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物 - Google Patents

ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物

Info

Publication number
JP2003503042A
JP2003503042A JP2001506778A JP2001506778A JP2003503042A JP 2003503042 A JP2003503042 A JP 2003503042A JP 2001506778 A JP2001506778 A JP 2001506778A JP 2001506778 A JP2001506778 A JP 2001506778A JP 2003503042 A JP2003503042 A JP 2003503042A
Authority
JP
Japan
Prior art keywords
sequence
peptide
peptide compound
cells
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001506778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003503042A5 (enExample
Inventor
ロンザン、クリストフ
スコット、ベロニク
トリエベル、フレデリック
Original Assignee
アンスティテュ・ギュスタブ−ルウシイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンスティテュ・ギュスタブ−ルウシイ filed Critical アンスティテュ・ギュスタブ−ルウシイ
Publication of JP2003503042A publication Critical patent/JP2003503042A/ja
Publication of JP2003503042A5 publication Critical patent/JP2003503042A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001506778A 1999-06-28 2000-06-27 ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物 Pending JP2003503042A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9908224A FR2795415B1 (fr) 1999-06-28 1999-06-28 Compose peptidique derive d'une orf decalee du gene ice
FR99/08224 1999-06-28
PCT/FR2000/001791 WO2001000784A2 (fr) 1999-06-28 2000-06-27 COMPOSE PEPTIDIQUE DERIVE D'UNE ORF DECALEE DU GENE iCE

Publications (2)

Publication Number Publication Date
JP2003503042A true JP2003503042A (ja) 2003-01-28
JP2003503042A5 JP2003503042A5 (enExample) 2008-04-03

Family

ID=9547371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001506778A Pending JP2003503042A (ja) 1999-06-28 2000-06-27 ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物

Country Status (9)

Country Link
US (1) US6875844B1 (enExample)
EP (1) EP1192179B1 (enExample)
JP (1) JP2003503042A (enExample)
AT (1) ATE309265T1 (enExample)
AU (1) AU5992500A (enExample)
CA (1) CA2377433A1 (enExample)
DE (1) DE60023891T2 (enExample)
FR (1) FR2795415B1 (enExample)
WO (1) WO2001000784A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535598A (ja) * 2013-11-08 2016-11-17 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ 哺乳類細胞内に外来性ミトコンドリアを導入するための方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7597894B2 (en) 2003-03-05 2009-10-06 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
WO2018035311A1 (en) * 2016-08-19 2018-02-22 Gray John T Compositions and methods for modulating gene expression using reading frame surveillance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029183A2 (en) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating t cells
AU7724398A (en) * 1997-06-06 1998-12-21 Regents Of The University Of California, The A melanoma associated antigen, t cell epitopes thereof and methods of using sa me
DE69837273T2 (de) * 1997-10-08 2008-01-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010022212, Ｂｉｏｃｈｅｍｉｃａｌ ａｎｄ Ｂｉｏｐｈｙｓｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ, 1997, Ｖｏｌ．２３３, ｐ．１１７−１２０ *
JPN6010022213, Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｂｉｏｃｈｅｍｉｃａｌ Ｃｈｅｍｉｓｔｒｙ, 1997, Ｖｏｌ．２７２， Ｎｏ．２３, ｐ．１４７６９−１４７７５ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535598A (ja) * 2013-11-08 2016-11-17 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ 哺乳類細胞内に外来性ミトコンドリアを導入するための方法

Also Published As

Publication number Publication date
ATE309265T1 (de) 2005-11-15
FR2795415B1 (fr) 2003-09-05
EP1192179A2 (fr) 2002-04-03
DE60023891D1 (de) 2005-12-15
WO2001000784A2 (fr) 2001-01-04
US6875844B1 (en) 2005-04-05
FR2795415A1 (fr) 2000-12-29
AU5992500A (en) 2001-01-31
WO2001000784A3 (fr) 2001-07-26
DE60023891T2 (de) 2006-07-27
CA2377433A1 (fr) 2001-01-04
EP1192179B1 (fr) 2005-11-09

Similar Documents

Publication Publication Date Title
Ronsin et al. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ
Bruggen et al. Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601
Bloom et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
van der Bruggen et al. Tumor antigens recognized by T lymphocytes
JP3998713B2 (ja) チロシナーゼ関連タンパク質１及び２のヒト癌抗原並びにこれをコードする遺伝子
JP3759738B2 (ja) 免疫原性ペプチド
AU749544B2 (en) Tumor antigen peptides originating in cyclophilin B
JP4900884B2 (ja) 腫瘍抗原
AU762903B2 (en) Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy
EP1021535B1 (en) Human cancer antigen ny eso-1/cag-3 and gene encoding same
KR20010024585A (ko) 종양-특이적 항원, 이들의 제조방법, 및 이들의 면역화 및진단에서의 용도
JP2010029194A (ja) 新規な腫瘍抗原タンパク質ｓａｒｔ−３、およびその腫瘍抗原ペプチド
JPH11502405A (ja) ｐ１５及びチロシナーゼ黒色腫抗原並びに診断及び治療方法におけるそれらの使用
JP3721437B2 (ja) 単離チロシナーゼ由来ペプチド抗原とその利用方法
JP2003503042A (ja) ｉＣＥ遺伝子のシフトされたＯＲＦ由来のペプチド化合物
JP2004535779A (ja) ヒトｍｄｍ２プロト腫瘍遺伝子より製造される腫瘍ペプチド抗原
JPWO2001011044A1 (ja) 腫瘍抗原
JPWO2000012701A1 (ja) 新規な腫瘍抗原タンパク質ｓａｒｔ−３、およびその腫瘍抗原ペプチド
US7084239B1 (en) Cancer peptides of NY-ESO-1/CAG-3
US20050025754A1 (en) Increased T-cell tumor infiltration by mutant light
WO2000032770A1 (fr) Nouvelle proteine d'antigene tumoral art-1 et peptide d'antigene tumoral de cette derniere
Vantomme et al. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16
EP1403283A1 (en) Tumor antigen
US7001600B1 (en) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
EP1806403A2 (en) Human cancer antigen NY ESO 1/CAG-3 and gene encoding same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101005